Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical rights issue prospectus in Swedish has been published

Regulatory information

On the 4th of March it was communicated that the board Hansa Medical AB (publ) has decided to implement a rights issue covering SEK 27 million with preferential rights to present Hansa Medical shareholders. The company has established a prospectus in Swedish regarding the rights issue, and the prospectus has been approved by and registered at Swedish Financial Supervisory Authority, Finansinspektionen, on 19th of March.The prospectus and a brief information folder, both in Swedish, are available at the company website www.hansamedical.com. In addition, the information folder will be distributed to Hansa Medicals shareholders. Prospectus and application forms in Swedish can be obtained free of cost from Remium AB at telephone +46 8-454 32 00 or e-mail emissioner@remium.com. Shareholders whose shares are nominee registered through a bank or a securities institution is advised to contact nominees for more information and instructions.